Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 19;501(7467):439-43.
doi: 10.1038/nature12442. Epub 2013 Aug 18.

Cross-neutralization of four paramyxoviruses by a human monoclonal antibody

Davide Corti  1 , Siro Bianchi, Fabrizia Vanzetta, Andrea Minola, Laurent Perez, Gloria Agatic, Barbara Guarino, Chiara Silacci, Jessica Marcandalli, Benjamin J Marsland, Antonio Piralla, Elena Percivalle, Federica Sallusto, Fausto Baldanti, Antonio Lanzavecchia
Affiliations

Cross-neutralization of four paramyxoviruses by a human monoclonal antibody

Davide Corti et al. Nature. .

Abstract

Broadly neutralizing antibodies reactive against most and even all variants of the same viral species have been described for influenza and HIV-1 (ref. 1). However, whether a neutralizing antibody could have the breadth of range to target different viral species was unknown. Human respiratory syncytial virus (HRSV) and human metapneumovirus (HMPV) are common pathogens that cause severe disease in premature newborns, hospitalized children and immune-compromised patients, and play a role in asthma exacerbations. Although antisera generated against either HRSV or HMPV are not cross-neutralizing, we speculated that, because of the repeated exposure to these viruses, cross-neutralizing antibodies may be selected in some individuals. Here we describe a human monoclonal antibody (MPE8) that potently cross-neutralizes HRSV and HMPV as well as two animal paramyxoviruses: bovine RSV (BRSV) and pneumonia virus of mice (PVM). In its germline configuration, MPE8 is HRSV-specific and its breadth is achieved by somatic mutations in the light chain variable region. MPE8 did not result in the selection of viral escape mutants that evaded antibody targeting and showed potent prophylactic efficacy in animal models of HRSV and HMPV infection, as well as prophylactic and therapeutic efficacy in the more relevant model of lethal PVM infection. The core epitope of MPE8 was mapped on two highly conserved anti-parallel β-strands on the pre-fusion viral F protein, which are rearranged in the post-fusion F protein conformation. Twenty-six out of the thirty HRSV-specific neutralizing antibodies isolated were also found to be specific for the pre-fusion F protein. Taken together, these results indicate that MPE8 might be used for the prophylaxis and therapy of severe HRSV and HMPV infections and identify the pre-fusion F protein as a candidate HRSV vaccine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mol Divers. 1996 Feb;1(2):87-96 - PubMed
    1. J Immunol. 2002 Mar 15;168(6):2944-52 - PubMed
    1. Nat Rev Microbiol. 2012 Jun 06;10(7):459-71 - PubMed
    1. Mol Biol Evol. 2011 Oct;28(10):2731-9 - PubMed
    1. Science. 2013 May 31;340(6136):1113-7 - PubMed

Publication types

MeSH terms

Associated data